US Stock MarketDetailed Quotes

LXEO Lexeo Therapeutics

Watchlist

6.670
+0.090+1.37%

Close Jan 2 16:00 ET

6.670
0.0000.00%

Post 16:20 ET

220.55MMarket Cap-2.55P/E (TTM)

Lexeo Therapeutics Stock Forum

Jaguar8

Nov 13, 2024 08:36

NEWS ER

$Lexeo Therapeutics (LXEO.US)$
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...

Jaguar8

Apr 22, 2024 06:31

$Lexeo Therapeutics (LXEO.US)$
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Moomoo AI

Dec 11, 2023 06:44

Lexeo's CEO acknowledged significant progress made in 2023, credited to the successful IPO. He anticipates more clinical data from cardiovascular and Alzheimer's disease programs in 2024.